 |
|
Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations
Laurent Kaiser, MD;
Cynthia Wat, MBBS, MRCP;
Tracy Mills, MSc;
Paul Mahoney, MSc;
Penelope Ward, MBBS;
Frederick Hayden, MD
Arch Intern Med. 2003;163:1667-1672.
Background Influenza causes lower respiratory tract complications (LRTCs), particularly bronchitis and pneumonia, in both otherwise healthy adults and those with underlying conditions. The aim of this study was to assess the effect of oseltamivir treatment on the incidence of LRTCs leading to antibiotic treatment and hospitalizations following influenza illness.
Methods We analyzed prospectively collected data on LRTCs and antibiotic use from 3564 subjects (age range, 13-97 years) with influenzalike illness enrolled in 10 placebo-controlled, double-blind trials of oseltamivir treatment.
Results In adults and adolescents with a proven influenza illness, oseltamivir treatment reduced overall antibiotic use for any reason by 26.7% (14.0% vs 19.1% with placebo; P<.001) and the incidence of influenza-related LRTCs resulting in antibiotic therapy by 55% (4.6% vs 10.3% with placebo; P<.001). In those subjects considered at increased risk of complications, 74 (18.5%) of 401 placebo recipients developed an LRTC leading to antibiotic use compared with 45 (12.2%) of 368 oseltamivir recipients (34.0% reduction; P = .02). Hospitalization for any cause occurred in 18 (1.7%) of 1063 placebo recipients compared with 9 (0.7%) of 1350 oseltamivir-treated patients (59% reduction; P = .02). In contrast, among subjects with an influenzalike illness but without a confirmed influenza infection, the incidence of LRTCs (6.7% vs 5.3%), overall antibiotic use (19.7% vs 19.3%), or hospitalizations (1.7% vs 1.9%) was similar between placebo and oseltamivir recipients, respectively.
Conclusion Oseltamivir treatment of influenza illness reduces LRTCs, antibiotic use, and hospitalization in both healthy and "at-risk" adults.
From the Hôpital Cantonal de Genève, Geneva, Switzerland (Dr Kaiser); Roche Global Development, Welwyn, England (Drs Wat and Ward, Ms Mills, and Mr Mahoney); and University of Virginia, Charlottesville (Dr Hayden). Dr Wat, Ms Mills, and Mr Mahoney are employees of F. Hoffman–La Roche Ltd. Dr Ward was employed by F. Hoffmann–La Roche Ltd when this research was conducted. Dr Hayden has served as a paid consultant to F. Hoffmann–La Roche Ltd according to the guidelines of the University of Virginia School of Medicine.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Martinez
Proc Am Thorac Soc 2007;4:647-658.
ABSTRACT
| FULL TEXT
Tamiflu and neuropsychiatric disturbance in adolescents
Maxwell
BMJ 2007;334:1232-1233.
FULL TEXT
Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects
Schentag et al.
J Clin Pharmacol 2007;47:689-696.
ABSTRACT
| FULL TEXT
Preparing for the next flu pandemic
Lim et al.
BMJ 2007;334:268-269.
FULL TEXT
Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic
Lim
Thorax 2007;62:1-46.
FULL TEXT
Use of neuraminidase inhibitors to combat pandemic influenza
Democratis et al.
J Antimicrob Chemother 2006;58:911-915.
ABSTRACT
| FULL TEXT
Pharmacokinetics of Oseltamivir in Young and Very Elderly Subjects
Abe et al.
The Annals of Pharmacotherapy 2006;40:1724-1730.
ABSTRACT
| FULL TEXT
Insights into the Interaction between Influenza Virus and Pneumococcus
McCullers
Clin. Microbiol. Rev. 2006;19:571-582.
ABSTRACT
| FULL TEXT
Pandemic influenza: using evidence on vaccines and antivirals for clinical decisions and policy making.
Granados et al.
Eur Respir J 2006;27:661-663.
FULL TEXT
Antibiotics in pandemic flu
Bonten and Prins
BMJ 2006;332:248-249.
FULL TEXT
Stockpiling oseltamivir: Roche clarifies data for improved mortality with oseltamivir
Smith and Dutkowski
BMJ 2005;331:1203-1203.
FULL TEXT
Management of Influenza Symptoms in Healthy Children: Cost-effectiveness of Rapid Testing and Antiviral Therapy
Rothberg et al.
Arch Pediatr Adolesc Med 2005;159:1055-1062.
ABSTRACT
| FULL TEXT
Neuraminidase inhibitors for influenza.
Moscona
NEJM 2005;353:1363-1373.
FULL TEXT
Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps?
Teo et al.
Arch. Dis. Child. 2005;90:532-536.
ABSTRACT
| FULL TEXT
Mechanism of Action of T-705 against Influenza Virus
Furuta et al.
Antimicrob. Agents Chemother. 2005;49:981-986.
ABSTRACT
| FULL TEXT
Antiviral Drugs for Prophylaxis and Treatment of Influenza
Obstet Gynecol 2005;105:427-429.
FULL TEXT
Case 9-2004 - An 18-Year-Old Man with Respiratory Symptoms and Shock
Gerberding et al.
NEJM 2004;350:1236-1247.
FULL TEXT
|
